DISTINGUISHING METASTATIC-LETHAL PROSTATE CANCER FROM INDOLENT PROSTATE CANCER USING METHYLATION STATUS OF EPIGENETIC MARKERS

摘要

Methods and kits to distinguish metastatic-lethal prostate cancer (PCa) from indolent PCa in a subject are described. The methods and kits utilize the methylation status of genetic markers. Distinguishing metastatic-lethal PCa from indolent PCa informs more directed treatments at an earlier time point than previously available.